Fiera Capital Corp Trims Stock Position in argenex SE (NASDAQ:ARGX)

Key Points

• Fiera Capital Corp decreased its stake in argenex SE by 0.5%, owning 154,416 shares valued at approximately $91.39 million after the sale of 844 shares.
• Brokerage firms have positive outlooks for argenex, with 19 analysts rating it as a buy and target prices ranging from $680.00 to $715.00, indicating strong investor confidence.
• Argentex SE reported robust quarterly earnings, with an EPS of $2.58, significantly exceeding the estimate of $2.32 and marking a net margin of 40.20%.

Fiera Capital Corp lowered its holdings in argenex SE (NASDAQ:ARGX - Free Report) by 0.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 154,416 shares of the company's stock after selling 844 shares during the quarter. Fiera Capital Corp owned 0.25% of argenex worth $91,393,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mackenzie Financial Corp grew its stake in shares of argenex by 3.4% in the first quarter. Mackenzie Financial Corp now owns 4,600 shares of the company's stock valued at $2,723,000 after buying an additional 151 shares in the last quarter. Nkcfo LLC grew its stake in shares of argenex by 32.7% in the first quarter. Nkcfo LLC now owns 146 shares of the company's stock valued at $86,000 after buying an additional 36 shares in the last quarter. LPL Financial LLC grew its stake in shares of argenex by 28.0% in the first quarter. LPL Financial LLC now owns 20,880 shares of the company's stock valued at $12,358,000 after buying an additional 4,563 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of argenex by 5.6% in the first quarter. Pacer Advisors Inc. now owns 833 shares of the company's stock valued at $493,000 after buying an additional 44 shares in the last quarter. Finally, Assetmark Inc. grew its stake in argenex by 3.2% during the 1st quarter. Assetmark Inc. now owns 8,926 shares of the company's stock worth $5,283,000 after purchasing an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenex Trading Up 0.6%

Shares of argenex stock traded up $4.20 on Friday, hitting $674.53. The stock had a trading volume of 475,812 shares, compared to its average volume of 373,593. argenex SE has a 52-week low of $475.65 and a 52-week high of $689.13. The stock has a market cap of $41.28 billion, a price-to-earnings ratio of 41.61, a P/E/G ratio of 1.07 and a beta of 0.37. The company's 50 day moving average price is $569.39 and its 200 day moving average price is $597.15.

argenex (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 16.15% and a net margin of 40.20%. The business had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. Analysts predict that argenex SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on ARGX shares. HC Wainwright boosted their target price on argenex from $720.00 to $774.00 and gave the stock a "buy" rating in a research note on Friday. Guggenheim boosted their target price on argenex from $1,060.00 to $1,070.00 and gave the stock a "buy" rating in a research note on Friday. Citigroup reissued a "buy" rating on shares of argenex in a research note on Wednesday, May 21st. Oppenheimer boosted their target price on argenex from $704.00 to $708.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, Wells Fargo & Company boosted their target price on argenex from $741.00 to $756.00 and gave the stock an "overweight" rating in a research note on Thursday. Nineteen research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $736.81.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.